ASH Annual Meeting

ASH Annual Meeting

Interviews from the American Society of Hematology’s Annual Meeting


Anjali Advani, MD: Vadastuximab Talirine in Treatment-Naïve CD33-Positive AML

Monotherapy with vadastuximab talirine led to high response rates in older patients with acute myeloid leukemia who are considered unfit for intensive chemotherapy. Dr....

Martin Schrappe, MD: Attempting to Reduce Chemotherapy Burden in Children With ALL

Dr. Schrappe discusses results of the AIEOP-BFM ALL 2000 trial, presented as a plenary abstract at the 2016 ASH Annual Meeting.

Investigational Drug BLU-285 Shows Tolerable Safety, Early Clinical Activity in Patients With Advanced Systemic...

Data from an ongoing phase I trial of BLU-285, an oral inhibitor of KIT D816V, in patients with advanced systemic mastocytosis (SM) suggest that...

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.